Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $25,214.35 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,905 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the transaction, the chief executive officer owned 605,408 shares of the company’s stock, valued at $2,585,092.16. This trade represents a 0.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, July 6th, Kevin Lee sold 1,737 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $4.31, for a total value of $7,486.47.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock opened at $4.18 on Friday. The stock’s 50-day simple moving average is $4.37 and its 200-day simple moving average is $5.22. The firm has a market capitalization of $291.81 million, a PE ratio of -1.33 and a beta of 1.55. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.92 and a fifty-two week high of $9.18.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%.The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $7.50 million. Sell-side analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCYC has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, April 10th. Morgan Stanley cut their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Truist Financial set a $8.00 target price on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Needham & Company LLC cut their price target on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $14.00.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Clearstead Advisors LLC grew its stake in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the period. GAMMA Investing LLC lifted its stake in shares of Bicycle Therapeutics by 512.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after purchasing an additional 6,447 shares during the period. Royal Bank of Canada lifted its stake in shares of Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock valued at $67,000 after purchasing an additional 3,788 shares during the period. Brooklyn Investment Group purchased a new stake in Bicycle Therapeutics during the fourth quarter worth $69,000. Finally, Ausdal Financial Partners Inc. purchased a new stake in Bicycle Therapeutics during the second quarter worth $70,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.